INCYTE CORPORATION |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 57.25 USD | -0.10% |
|
-0.26% | -8.82% |
| May. 23 | Deutsche Bank Initiates Incyte to Hold Rating With $55 Price Target | MT |
| May. 21 | Incyte Acquires 2 Office Buildings in Delaware | MT |
Financials (USD)
| Sales 2024 * | 4.09B | Sales 2025 * | 4.52B | Capitalization | 12.89B |
|---|---|---|---|---|---|
| Net income 2024 * | 759M | Net income 2025 * | 963M | EV / Sales 2024 * | 2.22 x |
| Net cash position 2024 * | 3.83B | Net cash position 2025 * | 5.41B | EV / Sales 2025 * | 1.66 x |
| P/E ratio 2024 * |
17.7
x | P/E ratio 2025 * |
14.2
x | Employees | 2,524 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.26% |
More Fundamentals
* Assessed data
More news
Latest transcript on Incyte Corporation
More recommendations
More press releases
More news
| 1 day | -0.10% | ||
| 1 week | -0.26% | ||
| Current month | +9.99% | ||
| 1 month | +10.78% | ||
| 3 months | -4.55% | ||
| 6 months | +8.63% | ||
| Current year | -8.82% |
1 week
56.62
58.19
1 month
50.3558.93
Current year
50.3567.37
1 year
50.2767.37
3 years
50.2788.26
5 years
50.27110.37
10 years
43.86153.15
| Managers | Title | Age | Since |
|---|---|---|---|
Herve Hoppenot
CEO | Chief Executive Officer | 64 | 14-01-12 |
| Director of Finance/CFO | 53 | 19-02-10 | |
Steven Stein
CTO | Chief Tech/Sci/R&D Officer | 57 | 15-03-01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Julian Baker
BRD | Director/Board Member | 57 | 00-12-31 |
Edmund Harrigan
BRD | Director/Board Member | 71 | 19-12-15 |
| Director/Board Member | 70 | 15-01-19 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 14.55% | 254 M€ | +12.51% | - | |
| 2.94% | 1 M€ | -0.95% | - | |
| 2.88% | 0 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-28 | 57.25 | -0.10% | 2,276,696 |
| 24-05-24 | 57.31 | -0.24% | 1,966,856 |
| 24-05-23 | 57.45 | -1.29% | 2,205,958 |
| 24-05-22 | 58.2 | +1.39% | 2,667,116 |
| 24-05-21 | 57.4 | +0.37% | 1,826,233 |
Delayed Quote Nasdaq, May 28, 2024 at 04:00 pm EDT
More quotes
Incyte Corporation specializes in the research & development of therapeutic products mainly intended for the treatment of cancers and inflammatory disorders. Net sales break down by revenue source as follows:
- product sales (85.6%);
- royalties (14.2%);
- income from research and cooperation agreements (0.2%).
Sector
Pharmaceuticals
Calendar
2024-06-10
- Goldman Sachs Global Healthcare Conference
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
57.25
USD
Average target price
72.8
USD
Spread / Average Target
+27.16%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -8.82% | 12.89B | |
| -2.34% | 90.28B | |
| -1.97% | 39.5B | |
| -15.47% | 31.71B | |
| +61.28% | 26.41B | |
| -22.81% | 14.34B | |
| -11.77% | 11.8B | |
| -45.97% | 10.95B | |
| +3.30% | 8.85B | |
| -13.92% | 7.53B |
- Stock Market
- Equities
- INCY Stock
